Zsofia K. Stadler, MD, on the Importance of Germline Analyses in Advanced Cancer

June 3, 2020

Germline analysis in patients with advanced cancer may play an important role in selecting FDA-approved treatments and clinical trial participation with germline-targeted therapeutics.

Germline analysis in patients with advanced cancer may play an important role in selecting FDA-approved treatments and clinical trial participation with germline-targeted therapeutics, according to a pan-cancer analysis presented at the 2020 ASCO Virtual Scientific Program.

In the analysis, 6.5% of patients (n = 11,975) who had germline genetic testing through a prospective protocol using MSK-IMPACT, a next-generation sequencing panel, harbored a targetable germline variant.

In a recent interview with CancerNetwork, Zsofia K. Stadler, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, spoke about the aim of the study, its results, and future studies that will be conducted.